Newamsterdam Pharma Company N.V. (NAMS) fundamentals score
Newamsterdam Pharma is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated. It seeks to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol (“LDL-C”) lowering therapy.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 3.5 out of 10, Weak long-term fundamentals
- Growth: 1.3/10
- Profitability: 1.0/10
- Financial health: 7.7/10
- Earnings quality: 7.4/10
- Valuation: 1.8/10
Scores are calculated from Newamsterdam Pharma Company N.V.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10